BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism
BridgeBio Pharma (Nasdaq: BBIO) announced upcoming presentations at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2025 in Seattle. The company will present Phase 2 data for encaleret in post-surgical hypoparathyroidism through an oral presentation by Dr. Iris Hartley from the National Institute of Dental and Craniofacial Research.
Additionally, two poster sessions focusing on skeletal dysplasia research will be presented by Dr. Bhavik Shah, showcasing data on infigratinib's effects on bone growth in hypochondroplasia and skull measures in Crouzon/Pfeiffer Syndromes mouse models.
BridgeBio Pharma (Nasdaq: BBIO) ha annunciato presentazioni all'American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2025 a Seattle. L'azienda presenterà i dati di Fase 2 sull'encaleret nella ipoparatiroidismo post-chirurgico tramite un intervento orale della Dr.ssa Iris Hartley del National Institute of Dental and Craniofacial Research.
Inoltre, due sessioni poster dedicate alla ricerca sulle discoplasie scheletriche saranno esposte dal Dott. Bhavik Shah, con dati sugli effetti dell'infigratinib sulla crescita ossea nell'ipocondroplasia e sulle misure craniche nei modelli murini delle sindromi di Crouzon/Pfeiffer.
BridgeBio Pharma (Nasdaq: BBIO) anunció presentaciones en la Reunión Anual 2025 de la American Society for Bone and Mineral Research (ASBMR) en Seattle. La compañía presentará datos de la Fase 2 sobre encaleret en el hipoparatiroidismo postoperatorio mediante una presentación oral de la Dra. Iris Hartley del National Institute of Dental and Craniofacial Research.
Además, dos sesiones de póster centradas en la investigación de las displasias esqueléticas serán presentadas por el Dr. Bhavik Shah, mostrando datos sobre los efectos de infigratinib en el crecimiento óseo en hipocondroplasia y en las medidas craneales en modelos murinos de los síndromes de Crouzon/Pfeiffer.
BridgeBio Pharma (Nasdaq: BBIO)는 시애틀에서 열리는 American Society for Bone and Mineral Research(ASBMR) 연례회의 2025에서의 발표 소식을 알렸습니다. 회사는 국립 치의학·구강두개연구소(National Institute of Dental and Craniofacial Research)의 아이리스 하틀리 박사에 의한 구두 발표를 통해 수술 후 부갑상선기능저하증에서의 엔칼레렛 2상 데이터를 공개할 예정입니다.
또한, 뼈 발달 이상(skeletal dysplasia) 연구에 초점을 맞춘 두 건의 포스터 세션이 바빅 샤 박사에 의해 발표되며, 하이포콘드로플라지아에서의 뼈 성장에 대한 인피그라티닙 효과 및 크로존/파이퍼 증후군 쥐 모델의 두개 측정 관련 데이터를 제시합니다.
BridgeBio Pharma (Nasdaq: BBIO) a annoncé des présentations lors de la réunion annuelle 2025 de l'American Society for Bone and Mineral Research (ASBMR) à Seattle. La société présentera des données de phase 2 sur l'encaleret dans l'hypoparathyroïdie post‑chirurgicale lors d'une présentation orale par la Dre Iris Hartley du National Institute of Dental and Craniofacial Research.
Par ailleurs, deux sessions d'affiches portant sur la recherche en dysplasie squelettique seront proposées par le Dr Bhavik Shah, présentant des données sur les effets de l'infigratinib sur la croissance osseuse dans l'hypochondroplasie et sur les mesures crâniennes dans des modèles murins des syndromes de Crouzon/Pfeiffer.
BridgeBio Pharma (Nasdaq: BBIO) kündigte Präsentationen auf dem American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2025 in Seattle an. Das Unternehmen wird Phase‑2‑Daten zu Encaleret bei postoperativem Hypoparathyreoidismus in einem Vortrag von Dr. Iris Hartley vom National Institute of Dental and Craniofacial Research vorstellen.
Zusätzlich werden zwei Posterpräsentationen zur Forschung an Skelettdysplasien von Dr. Bhavik Shah gezeigt, die Daten zu den Effekten von Infigratinib auf das Knochenwachstum bei Hypochondroplasie und zu Schädelmaßen in Mausmodellen der Crouzon-/Pfeiffer‑Syndrome präsentieren.
- None.
- None.
PALO ALTO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that an oral presentation of Phase 2 data in post-surgical hypoparathyroidism and two poster sessions on skeletal dysplasia data will be shared at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2025, taking place in Seattle, WA from September 5 - 8, 2025.
Post-Surgical Hypoparathyroidism Oral Presentation:
The Oral Calcilytic Encaleret Reduced Urinary Calcium While Maintaining Blood Calcium in Individuals with Post-Surgical Hypoparathyroidism
Presenter: Iris Hartley, M.D., National Institute of Dental and Craniofacial Research, National Institutes of Health
Date/time: Saturday, September 6 at 11:30 am PT
Skeletal Dysplasia Poster Sessions:
Infigratinib Low Dose Therapy Is an Effective Strategy in Improving Bone Growth in a Hypochondroplasia Mouse Model
Presenter: Bhavik Shah, Ph.D., Senior Vice President of Research, Genetic Medicine, Skeletal Dysplasia, BridgeBio
Date/time: Friday, September 5 at 5:00 pm PT and Sunday, September 7 at 2:00 pm PT
Infigratinib Improves Skull Measures in a Mouse Model of Crouzon/Pfeiffer Syndromes
Presenter: Bhavik Shah, Ph.D., Senior Vice President of Research, Genetic Medicine, Skeletal Dysplasia, BridgeBio
Date/time: Saturday, September 6 at 2:00 pm PT
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, Instagram, and YouTube.
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com
(650)-789-8220
BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com
FAQ
When will BridgeBio (BBIO) present its Phase 2 encaleret data at ASBMR 2025?
What is the focus of BridgeBio's (BBIO) encaleret Phase 2 presentation?
What skeletal dysplasia research is BridgeBio (BBIO) presenting at ASBMR 2025?
Who are the key presenters for BridgeBio (BBIO) at ASBMR 2025?
